Arch Biopartners Inc. (ARCH.V)
CAD 1.73
(-0.57%)
CAD 1.73
(-0.57%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.32 Million CAD | -208.02% |
| 2022 | -1.08 Million CAD | 7.67% |
| 2021 | -1.16 Million CAD | 74.73% |
| 2020 | -4.62 Million CAD | -96.33% |
| 2019 | -2.35 Million CAD | 26.28% |
| 2018 | -3.19 Million CAD | -67.94% |
| 2017 | -1.9 Million CAD | -89.2% |
| 2016 | -1 Million CAD | -19.97% |
| 2015 | -839 Thousand CAD | -110.54% |
| 2014 | -398.5 Thousand CAD | -109.8% |
| 2013 | -189.95 Thousand CAD | 42.32% |
| 2012 | -329.31 Thousand CAD | 26.21% |
| 2011 | -446.26 Thousand CAD | 93.81% |
| 2010 | -7.21 Million CAD | -54.91% |
| 2009 | -4.65 Million CAD | -608.06% |
| 2008 | -657.52 Thousand CAD | -81.9% |
| 2007 | -361.47 Thousand CAD | -1884.16% |
| 2006 | -18.21 Thousand CAD | 95.06% |
| 2005 | -368.97 Thousand CAD | 71.11% |
| 2004 | -1.27 Million CAD | -145.93% |
| 2003 | -519.3 Thousand CAD | -70.61% |
| 2002 | -304.38 Thousand CAD | 87.31% |
| 2001 | -2.39 Million CAD | -125.41% |
| 2000 | -1.06 Million CAD | -26.88% |
| 1999 | -838.66 Thousand CAD | -9.84% |
| 1998 | -763.53 Thousand CAD | 71.22% |
| 1997 | -2.65 Million CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -783.25 Thousand CAD | -420.63% |
| 2024 Q3 | -884.56 Thousand CAD | 22.98% |
| 2024 Q2 | -1.14 Million CAD | -46.63% |
| 2023 Q3 | -450.78 Thousand CAD | 49.03% |
| 2023 FY | -3.32 Million CAD | -208.02% |
| 2023 Q4 | 244.28 Thousand CAD | 154.19% |
| 2023 Q2 | -884.4 Thousand CAD | 56.58% |
| 2023 Q1 | -2.03 Million CAD | -479.09% |
| 2022 Q1 | -174.75 Thousand CAD | -126.42% |
| 2022 Q3 | -196.94 Thousand CAD | 52.99% |
| 2022 FY | -1.08 Million CAD | 7.67% |
| 2022 Q4 | -351.74 Thousand CAD | -78.6% |
| 2022 Q2 | -418.91 Thousand CAD | -139.72% |
| 2021 Q2 | -1.05 Million CAD | 36.31% |
| 2021 FY | -1.16 Million CAD | 74.73% |
| 2021 Q4 | 661.36 Thousand CAD | -24.61% |
| 2021 Q3 | 877.24 Thousand CAD | 183.35% |
| 2021 Q1 | -1.65 Million CAD | -2.64% |
| 2020 Q3 | -2.19 Million CAD | -2197.24% |
| 2020 Q1 | -733.04 Thousand CAD | 24.73% |
| 2020 FY | -4.62 Million CAD | -96.33% |
| 2020 Q4 | -1.61 Million CAD | 26.49% |
| 2020 Q2 | -95.34 Thousand CAD | 86.99% |
| 2019 Q4 | -973.94 Thousand CAD | -1099.85% |
| 2019 Q3 | -81.17 Thousand CAD | 84.2% |
| 2019 FY | -2.35 Million CAD | 26.28% |
| 2019 Q2 | -513.74 Thousand CAD | 37.22% |
| 2019 Q1 | -818.27 Thousand CAD | -4.08% |
| 2018 Q2 | -584.09 Thousand CAD | -70.91% |
| 2018 Q1 | -341.76 Thousand CAD | -55.18% |
| 2018 FY | -3.19 Million CAD | -67.94% |
| 2018 Q4 | -786.22 Thousand CAD | 47.1% |
| 2018 Q3 | -1.48 Million CAD | -154.43% |
| 2017 Q4 | -220.23 Thousand CAD | 83.14% |
| 2017 Q3 | -1.3 Million CAD | -746.5% |
| 2017 FY | -1.9 Million CAD | -89.2% |
| 2017 Q1 | -235.35 Thousand CAD | 31.75% |
| 2017 Q2 | -154.32 Thousand CAD | 34.43% |
| 2016 Q3 | -182.81 Thousand CAD | 43.38% |
| 2016 FY | -1 Million CAD | -19.97% |
| 2016 Q1 | -156.04 Thousand CAD | -6.8% |
| 2016 Q2 | -322.86 Thousand CAD | -106.9% |
| 2016 Q4 | -344.84 Thousand CAD | -88.64% |
| 2015 FY | -839 Thousand CAD | -110.54% |
| 2015 Q2 | -168.16 Thousand CAD | 53.14% |
| 2015 Q3 | -165.86 Thousand CAD | 1.36% |
| 2015 Q4 | -146.1 Thousand CAD | 11.91% |
| 2015 Q1 | -358.86 Thousand CAD | -129.81% |
| 2014 Q1 | -52.87 Thousand CAD | 10.38% |
| 2014 Q2 | -58.61 Thousand CAD | -10.87% |
| 2014 Q4 | -156.15 Thousand CAD | -19.33% |
| 2014 FY | -398.5 Thousand CAD | -109.8% |
| 2014 Q3 | -130.86 Thousand CAD | -123.25% |
| 2013 Q2 | -80.24 Thousand CAD | -145.98% |
| 2013 Q4 | -58.99 Thousand CAD | -226.27% |
| 2013 Q1 | -32.62 Thousand CAD | 64.94% |
| 2013 Q3 | -18.08 Thousand CAD | 77.47% |
| 2013 FY | -189.95 Thousand CAD | 42.32% |
| 2012 Q2 | -59.82 Thousand CAD | 31.41% |
| 2012 Q4 | -93.04 Thousand CAD | -4.28% |
| 2012 FY | -329.31 Thousand CAD | 26.21% |
| 2012 Q3 | -89.22 Thousand CAD | -49.14% |
| 2012 Q1 | -87.22 Thousand CAD | 1.86% |
| 2011 Q4 | -88.87 Thousand CAD | 48.76% |
| 2011 FY | -446.26 Thousand CAD | 93.81% |
| 2011 Q3 | -173.46 Thousand CAD | -127.21% |
| 2011 Q2 | -76.34 Thousand CAD | 29.04% |
| 2011 Q1 | -107.58 Thousand CAD | -33.93% |
| 2010 Q2 | -24.03 Thousand CAD | 75.61% |
| 2010 FY | -7.21 Million CAD | -54.91% |
| 2010 Q4 | -80.33 Thousand CAD | 98.87% |
| 2010 Q3 | -7.1 Million CAD | -29443.32% |
| 2010 Q1 | -98.57 Thousand CAD | -268.27% |
| 2009 Q4 | -26.76 Thousand CAD | 99.47% |
| 2009 FY | -4.65 Million CAD | -608.06% |
| 2009 Q2 | 549.65 Thousand CAD | 293.67% |
| 2009 Q3 | -5.07 Million CAD | -1024.21% |
| 2009 Q1 | -283.81 Thousand CAD | -2118.36% |
| 2008 Q4 | -12.79 Thousand CAD | 92.71% |
| 2008 Q3 | -175.47 Thousand CAD | 5.37% |
| 2008 FY | -657.52 Thousand CAD | -81.9% |
| 2008 Q2 | -185.43 Thousand CAD | 10.01% |
| 2008 Q1 | -206.07 Thousand CAD | -270.38% |
| 2007 Q2 | -65.87 Thousand CAD | -133.16% |
| 2007 FY | -361.47 Thousand CAD | -1884.16% |
| 2007 Q4 | -55.63 Thousand CAD | -64.17% |
| 2007 Q3 | -33.89 Thousand CAD | 48.55% |
| 2007 Q1 | 198.63 Thousand CAD | 435.69% |
| 2006 FY | -18.21 Thousand CAD | 95.06% |
| 2006 Q4 | -59.17 Thousand CAD | -19.35% |
| 2006 Q3 | -49.57 Thousand CAD | 54.14% |
| 2006 Q2 | -108.1 Thousand CAD | 41.78% |
| 2006 Q1 | -185.68 Thousand CAD | -242.7% |
| 2005 Q2 | -172.58 Thousand CAD | 78.52% |
| 2005 Q1 | -803.56 Thousand CAD | -117.08% |
| 2005 FY | -368.97 Thousand CAD | 71.11% |
| 2005 Q4 | 130.11 Thousand CAD | 192.4% |
| 2005 Q3 | -140.82 Thousand CAD | 18.4% |
| 2004 FY | -1.27 Million CAD | -145.93% |
| 2004 Q1 | -330.51 Thousand CAD | -238.88% |
| 2004 Q2 | -123.04 Thousand CAD | 62.77% |
| 2004 Q3 | 22.32 Thousand CAD | 118.15% |
| 2004 Q4 | -370.16 Thousand CAD | -1757.85% |
| 2003 Q1 | -132.9 Thousand CAD | -671.49% |
| 2003 FY | -519.3 Thousand CAD | -70.61% |
| 2003 Q4 | -97.53 Thousand CAD | -525.4% |
| 2003 Q3 | -15.59 Thousand CAD | 79.39% |
| 2003 Q2 | -75.66 Thousand CAD | 43.07% |
| 2002 FY | -304.38 Thousand CAD | 87.31% |
| 2002 Q3 | -82.08 Thousand CAD | -13.74% |
| 2002 Q4 | -17.22 Thousand CAD | 79.01% |
| 2002 Q1 | -2.03 Million CAD | -2161.64% |
| 2002 Q2 | -72.16 Thousand CAD | 96.45% |
| 2001 Q4 | -89.85 Thousand CAD | 61.9% |
| 2001 Q3 | -235.8 Thousand CAD | -474.46% |
| 2001 Q2 | -41.04 Thousand CAD | 91.28% |
| 2001 Q1 | -470.77 Thousand CAD | -101.68% |
| 2001 FY | -2.39 Million CAD | -125.41% |
| 2000 Q2 | -59.11 Thousand CAD | 89.4% |
| 2000 FY | -1.06 Million CAD | -26.88% |
| 2000 Q1 | -557.43 Thousand CAD | -565.37% |
| 2000 Q4 | -233.42 Thousand CAD | 22.4% |
| 2000 Q3 | -300.81 Thousand CAD | -408.9% |
| 1999 Q4 | -83.77 Thousand CAD | 34.7% |
| 1999 FY | -838.66 Thousand CAD | -9.84% |
| 1999 Q1 | -524.85 Thousand CAD | -847.56% |
| 1999 Q2 | -69.15 Thousand CAD | 86.82% |
| 1999 Q3 | -128.29 Thousand CAD | -85.5% |
| 1998 FY | -763.53 Thousand CAD | 71.22% |
| 1998 Q4 | -55.39 Thousand CAD | 56.69% |
| 1998 Q2 | -127.9 Thousand CAD | 0.0% |
| 1998 Q3 | -127.9 Thousand CAD | 0.0% |
| 1997 FY | -2.65 Million CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Covalon Technologies Ltd. | -4.46 Million CAD | 25.426% |
| Hemostemix Inc. | -2.5 Million CAD | -32.957% |
| Universal Ibogaine Inc. | -10.49 Million CAD | 68.305% |
| Kane Biotech Inc. | -5.03 Million CAD | 33.916% |
| MedMira Inc. | -2.67 Million CAD | -24.333% |
| Marvel Biosciences Corp. | -2.29 Million CAD | -45.184% |
| NervGen Pharma Corp. | -22.38 Million CAD | 85.137% |
| XORTX Therapeutics Inc. | -2.85 Million CAD | -16.345% |